Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2006

View Archived Issues

Indian approval for phase II study of crofelemer in acute infectious diarrhea

MAP-0010 studied for asthma in new phase II trial

BDSI acquires non-U.S. BEMA rights, licenses BEMA Fentanyl to Meda for Europe

Antitumor activity of a novel lignan isolated from Chinese herbal medicine

Amorfix Life Sciences and Biogen Idec to collaborate in ALS

Icagen implements DMC's recommendations in phase III study of ICA-17043

SPA for pivotal study of Fodosine in T-cell leukemia

Allon seeks clearance to add Canadian sites to phase II study of AL-208

Arpida cleared for U.K. microdose study of AR-709

Phase I study for NGX-426, oral prodrug of tezampanel

Phase II study of INS-50589 Antiplatelet terminated after bleeding complications

PRX-08066 studied for pulmonary hypertension associated with COPD

Fast track designation for NOV-002 in NSCLC

Diamyd sublicenses use of GAD65 gene to Neurologix for Parkinson's disease

European submission for Avastin in NSCLC

Inflammatory bowel disease compound NV-52 continues phase I testing

HCV-I.E.T. shows signs of efficacy in HCV nonresponders

TopoTarget's post-extravasation drug approved in Europe, approvable in U.S.

New compounds targeting cardiovascular diseases disclosed in recent patent literature

Mexico first to approve Januvia

Allergan patents novel prostanoid EP2 agonists for glaucoma

Recent patents disclose new agents for arthritis, autoimmune disorders, etc.

Promising antitumor activity of novel photodynamic agents

Novel PARP-1 inhibitor protects Huntington's disease cells from oxidative damage in vitro

Blocking adenosine A2B receptor with CVT-6883 reduces pulmonary inflammation and injury in vivo

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...